Abstract: The horn switch assembly includes a fixed plate on a connector arm and a movable plate in an air bag module. When those plates are electrically continuous, a horn sounds. The movable plate is urged upward apart from the fixed plate. The movable plate is disposed such that a distance from the movable plate to the fixed plate is set at a fixed distance by two mounting bolts, screwed into the connector arm. Fore-spoke arm sections include torsional deformation parts, torsionally deformable, located outside the mounting seats of an air bag module. Back-spoke arm sections include first bending deformation parts located on the inner side of the mounting seats of the air bag module, and second bending deformation parts located on the outer side of the mounting seats and a column cover. The first bending deformation part has a lower bending rigidity than the second bending deformation part. A lower cover is made of synthetic resin, e.g.

Abstract: A flexible lustered product used in automobiles. The flexible lustered product includes a base material made of resin. A base coat layer is applied to at least a portion of the surface of the base material. The base coat layer has a glass transition point that is at least minus 30° C. and at most 0° C. The base coat layer includes a silane coupling agent having an epoxy group. A metal film layer is applied to at least a portion of the surface of the base coat layer. The metal film layer is anticorrosive and has a thickness that is at least 150 Å and at most 800 Å. The metal film layer is formed by a plurality of metal particles disposed in contact with one another so as to define a grain boundary between adjacent metal particles. A top coat layer is applied to at least a portion of the surface of the metal film layer. The top coat layer includes an ultraviolet ray absorbent and a silane coupling agent having an epoxy group.

Abstract: A solid rocket propellant formulation with a burn rate slope of less than about 0.15 ips/psi over a substantial portion of a pressure range of about 1,000 psi to about 7,000 psi and a temperature sensitivity of less than about 0.15%/.degree. F. is provided. A high performance solid propellant rocket motor including the solid rocket propellant formulation is also provided. The rocket motor is encased in a high strength low weight motor casing which is further equipped with a nozzle throat constructed of material that has an erosion rate not more than about 2 to about 3 mils per second during motor operation. The solid rocket propellant formulation can be cast in a grain pattern such that an all-boost thrust profile is achieved.

Abstract: Novel strains of the insecticidal microorganism Bacillus thurinaiensis are described. These contain novel genes, and in particular a gene coding for a novel insecticidal endotoxin, 81 kilodaltons in length, toxic to both Lepidoptera and Coleoptera. The novel strains and the genes they contain may be used to combat insect attack against plants.

Abstract: Polysubstituted cyclopentadiene compound wherein at least two different substituents are present from the group consisting of linear, branched and cyclic alkyls, aralkyls and alkenyls, and a process for the preparation of a cyclopentadiene compound substituted with at least two different groups chosen from the group consisting of linear, branched, cyclic and aromatic alkyls and alkenyls, characterized in that it comprises the reacting of a halide of a first substituting group in a mixture of the cyclopentadiene compound and an aqueous solution of a base, in which the quantity of the base relative to the cyclopentadiene compound is between 5 and 30 mol/mol, in the presence of a phase transfer catalyst, followed by the addition of a halide of a second or optionally a third substituting group to the reaction mixture.

Abstract: A propylene-ethylene random copolymer prepared by copolymerizing propylene with ethylene in the substantial absence of a liquid medium with a catalyst system comprising:(A) a solid catalyst component containing magnesium, titanium, a halogen and a first electron donor as an essential component,(B) an organoaluminum compound and(C) a second electron donor compound, wherein an ethylene content (E) of the copolymer is from 3.5 to 7.0% by weight, and wherein a content of a xylene-soluble portion at 20.degree. C. (D) of the copolymer satisfies the relationship D.ltoreq.E+2.0 (% by weight). Films of the copolymer have an excellent appearance (little bleed whitening) and an excellent balance between low-temperature heat-sealing property and rigidity.

Abstract: The invention relates to a process for the preparation of a thermoplastic elastomer comprising preparing a blend of a rubber and a thermoplastic resin, in which the rubber is at least partially vulcanized by using a phenolic curative. The invention is that, to overcome problems with surface quality, an effective amount of a Lewis base is added after the desired degree of vulcanization of the rubber is obtained.The invention also relates to a process for the preparation of an UV-stable thermoplastic elastomer.

Abstract: A fuel tank cap structure which enables a cover member to be readily attached to a casing body. The fuel tank cap includes the casing body and the cover member that is rotatable in one direction relative to the casing body via a ratchet mechanism when a torque of or above a predetermined level is applied to the cover member. The cover member has fitting projections that are held by an outer ring member of the casing body. The outer ring member has a plurality of slits, which cause the outer ring member to be elastically deformed when riding over the fitting projections, thereby facilitating the engagement of the fitting projections with the outer ring member.

Abstract: The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methyl-benzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.

Abstract: A fuel tank cap structure and method of manufacturing which prevents a parting line formed on a cover member in the process of injection molding from being undesirably shaven. The fuel tank cap includes a casing body and a cover member that is rotatable in one direction relative to the casing body via a ratchet mechanism when a torque of or above a predetermined level is applied to the cover member. The cover member has fitting projections that are held by an outer ring member of the casing body. A slide mold is used for manufacturing the cover member having the fitting projections that are undercut in the injection molding. This causes a parting line to be formed on a top wall of the cover member. Anti-shaving projections formed at substantially the same height as that of the parting line prevent the parting line from being slid against the outer ring member and shaven.

Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.

Abstract: A passive reservoir for medicament in the form of a plastics bag 1, has a hanging eyelet 2 at its upper end and a lower outlet nozzle 3. The plastics bag 1 has bottom corners 4,5, the left-hand right-angled corner 5 of which encapsulates a data carrier means 6 which carries data relating to a medicament contained or to be contained within the bag 1. The data carrier means is in the form of an electrically and/or magnetically operable device which can emit the data it is carrying in response to activation by a suitable field applied by an external reading device, which can cooperate with a delivery device to control the delivery to a patient of medicament when contained in the bag 1.

Abstract: A fuel cap structure which enables part of a flange member to be readily broken when an external force is applied via a cover member in any direction. A fuel cap includes a casing body and a cover member attached to the flange member formed on the upper portion of the casing body. The flange member includes a joint member to join the upper portion of the casing body with an outer ring member, in which the cover member is fitted. The joint member has fragile portions including notches. Each fragile portion starts a break of the joint member when an external force is applied to the flange member via the cover member in a variety of directions.

Abstract: The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Abstract: Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.

Abstract: The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy;n is 1, 2 or 3;each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.

Abstract: The invention concerns the quinazoline derivative 6-(2-methoxyethylamino)-7-methoxy-4-(3'-methylanilino)quinazoline, or a pharmaceutically-acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing the compound and the use of the receptor tyrosine kinase inhibitory properties of the compound in the treatments of proliferative disease such as cancer.

Abstract: Yeast Artificial Chromosomes (YACS) containing DNA encoding the cystic fibrosis (CFTR) gene are described. The YACs allow detailed analysis of the coding and non-coding regions of the gene and the determination of cystic fibrosis alleles in sample DNA from an individual or individuals.

Abstract: A hand lever device includes a housing (15A, 15B) and a main lever (30) pivotally attached to the housing (15A, 15B). The main lever (30) is connected to one end (22a) of an inner cable (22) extending through an outer tube (21) of a Bowden cable (20) for controlling a driven member (CV). The outer tube (21) is provided with a shifting mechanism (40), such as a threaded member shifting mechanism (41, 45), for forcibly shifting one end (21a) of the outer tube (21) along the longitudinal direction of the inner cable (22).

Abstract: A (substituted-aralkyl)heterocyclic compound of the formula I ##STR1## wherein R.sup.1 is an azido, carbamoyl, cyano, formyl, hydroxy or nitro radical, a 1-6C 1-hydroxyalkyl, alkoxy, alkylcarbamoyl, alkylthio, alkylsulphinyl or alkylsulphonyl radical, a 2-cyanoethyl radical, optionally bearing one to four 1-6C alkyl substituents, or a 2-6C alkanoyl, halogenoalkanoyl, alkanoyloxy, alkanoylamino, dialkylcarbamoyl or alkoxycarbonyl radical; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, dueterioalkyl or halogenoalkyl radical, or a phenyl or phenyl(1-6C alkyl) radical, in each of which the phenyl may optionally bear one or more substituents; or R.sup.2 and R.sup.3, together with the carbon atom to which they are attached, may form a 3- to 6-membered ring; or R.sup.1 R.sup.2 R.sup.3 C- is a 1,1-dicyanoethyl or trifluoromethylsulphonyl radical; R.sup.4 is a hydrogen or halogen atom, a cyano or nitro radical or a 1-6C alkyl or halogenoalkyl radical; R.sup.